Literature DB >> 17107947

The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR.

Ji-Young Cha1, Joyce J Repa.   

Abstract

The liver X receptors, LXRalpha (NR1H3) and LXRbeta (NR1H2), are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. LXRs play a critical role in cholesterol homeostasis and bile acid metabolism. In addition, oral administration of LXR agonists to mice results in elevated hepatic fatty acid synthesis and steatosis and increased secretion of triglyceride-rich very low density lipoprotein resulting in hypertriglyceridemia. This increased hepatic lipogenesis has been largely attributed to the LXR-dependent up-regulation of sterol regulatory element-binding protein 1c (SREBP-1c) expression. However, it has been reported that treating Srebp-1c null mice with the synthetic LXR agonist T0901317 still results in enhanced expression of many lipogenic genes, suggesting additional mechanisms by which LXR can enhance hepatic lipogenesis. In this report, we identify the carbohydrate response element-binding protein (ChREBP) as an LXR target that independently enhances the up-regulation of select lipogenic genes. The ChREBP promoter contains functional LXR-binding sites that confer receptor-dependent binding and transactivation. We show that T0901317 treatment of mice is associated with up-regulation of the ChREBP target gene, liver-type pyruvate kinase. Therefore, activation of LXR not only increases ChREBP mRNA via enhanced transcription but also modulates ChREBP activity. This establishes LXR as a master lipogenic transcription factor, as it directly regulates both SREBP-1c and ChREBP to enhance hepatic fatty acid synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107947     DOI: 10.1074/jbc.M605023200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  158 in total

Review 1.  Liver X receptors, atherosclerosis and inflammation.

Authors:  Daryn R Michael; Tim G Ashlin; Melanie L Buckley; Dipak P Ramji
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.

Authors:  Thomas Pfeifer; Marlene Buchebner; Prakash G Chandak; Jay Patankar; Adelheid Kratzer; Sascha Obrowsky; Gerald N Rechberger; Rajendra S Kadam; Uday B Kompella; Gerhard M Kostner; Dagmar Kratky; Sanja Levak-Frank
Journal:  Curr Pharm Biotechnol       Date:  2011-02-01       Impact factor: 2.837

3.  Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity.

Authors:  Christian Bindesbøll; Qiong Fan; Rikke C Nørgaard; Laura MacPherson; Hai-Bin Ruan; Jing Wu; Thomas Å Pedersen; Knut R Steffensen; Xiaoyong Yang; Jason Matthews; Susanne Mandrup; Hilde I Nebb; Line M Grønning-Wang
Journal:  J Lipid Res       Date:  2015-02-27       Impact factor: 5.922

Review 4.  Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?

Authors:  Anne P L Jensen-Urstad; Clay F Semenkovich
Journal:  Biochim Biophys Acta       Date:  2011-10-08

5.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

6.  Increased lipid synthesis and decreased β-oxidation in the liver of SHR/NDmcr-cp (cp/cp) rats, an animal model of metabolic syndrome.

Authors:  Shizuyo Tanaka; Tohru Yamazaki; Satoshi Asano; Atsushi Mitsumoto; Daisuke Kobayashi; Naomi Kudo; Yoichi Kawashima
Journal:  Lipids       Date:  2013-09-18       Impact factor: 1.880

7.  Epigenetic histone methylation regulates transforming growth factor β-1 expression following bile duct ligation in rats.

Authors:  Shyr-Ming Sheen-Chen; Chung-Ren Lin; Kuan-Hung Chen; Chien-Hui Yang; Chien-Te Lee; Hui-Wen Huang; Chun-Ying Huang
Journal:  J Gastroenterol       Date:  2013-10-06       Impact factor: 7.527

8.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

Review 9.  Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation.

Authors:  Yan-Yun Liu; Gregory A Brent
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

10.  25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway.

Authors:  Yongjie Ma; Leyuan Xu; Daniel Rodriguez-Agudo; Xiaobo Li; Douglas M Heuman; Phillip B Hylemon; William M Pandak; Shunlin Ren
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.